DrugPatentWatch Database Preview
Botulinum toxin type b - Biologic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for botulinum toxin type b
| Tradenames: | 1 |
| Patents: | 74 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for botulinum toxin type b |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for botulinum toxin type b |
Recent Clinical Trials for botulinum toxin type b
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Kaiser Permanente | Phase 3 |
| University of Texas Southwestern Medical Center | Phase 3 |
| Women and Infants Hospital of Rhode Island | Phase 3 |
Recent Litigation for botulinum toxin type b
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Halozyme, Inc. v. Lee | 2016-12-19 |
Pharmacology for botulinum toxin type b
| Mechanism of Action | Acetylcholine Release Inhibitors |
Company Disclosures: US Patents for botulinum toxin type b
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-06-10 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for botulinum toxin type b
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-02-15 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for botulinum toxin type b
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1316906 | Start Trial |
| China | 1658897 | Start Trial |
| Japan | 2005530770 | Start Trial |
| Japan | 2017060862 | Start Trial |
| Israel | 220721 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for botulinum toxin type b
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0822 | Netherlands | Start Trial | PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326 |
| C/GB12/053 | United Kingdom | Start Trial | PRODUCT NAME: BOTULINUM TOXIN; REGISTERED: UK PL 00426/0074-0110 20120924; UK PL 00426/0118-0030 20120924; UK PL 00426/0119-0012 20120924; REASON FOR LAPSE: SURRENDERED |
| 2008000043 | Germany | Start Trial | PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531 |
| 2015031 | Lithuania | Start Trial | PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| C/GB10/013 | United Kingdom | Start Trial | PRODUCT NAME: BOTULINUM TOXIN TYPE B; REGISTERED: UK EU/1/00/166/001-003 20010125 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
